[go: up one dir, main page]

MX2017005669A - Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. - Google Patents

Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Info

Publication number
MX2017005669A
MX2017005669A MX2017005669A MX2017005669A MX2017005669A MX 2017005669 A MX2017005669 A MX 2017005669A MX 2017005669 A MX2017005669 A MX 2017005669A MX 2017005669 A MX2017005669 A MX 2017005669A MX 2017005669 A MX2017005669 A MX 2017005669A
Authority
MX
Mexico
Prior art keywords
preparation
derivatives
therapeutic use
bencilo
hydroxide
Prior art date
Application number
MX2017005669A
Other languages
English (en)
Other versions
MX375725B (es
Inventor
Meneyrol Jérôme
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2017005669A publication Critical patent/MX2017005669A/es
Publication of MX375725B publication Critical patent/MX375725B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a derivados de hidróxido de bencilo de la fórmula (I): (ver Fórmula) La invención también se refiere a la preparación y el uso terapéutico de los compuestos de la fórmula (I).
MX2017005669A 2014-10-30 2015-10-29 Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. MX375725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306747.8A EP3015459A1 (en) 2014-10-30 2014-10-30 Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof
PCT/EP2015/075112 WO2016066742A1 (en) 2014-10-30 2015-10-29 Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
MX2017005669A true MX2017005669A (es) 2017-08-07
MX375725B MX375725B (es) 2025-03-06

Family

ID=51904926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005669A MX375725B (es) 2014-10-30 2015-10-29 Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Country Status (24)

Country Link
US (1) US9878990B2 (es)
EP (2) EP3015459A1 (es)
JP (1) JP6644067B2 (es)
KR (1) KR102598818B1 (es)
CN (1) CN107074777B (es)
AR (1) AR102481A1 (es)
AU (1) AU2015340584B2 (es)
BR (1) BR112017008057B1 (es)
CA (1) CA2963601C (es)
CY (1) CY1121388T1 (es)
DK (1) DK3212622T3 (es)
ES (1) ES2703579T3 (es)
HR (1) HRP20182167T1 (es)
HU (1) HUE041581T2 (es)
IL (1) IL251930B (es)
LT (1) LT3212622T (es)
MX (1) MX375725B (es)
PL (1) PL3212622T3 (es)
PT (1) PT3212622T (es)
RU (1) RU2704017C2 (es)
SG (1) SG11201702555UA (es)
SI (1) SI3212622T1 (es)
TW (1) TWI719952B (es)
WO (1) WO2016066742A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010105064A (ko) * 2000-05-18 2001-11-28 함종천 삼백초로부터 추출한 화합물 hnp-98701a,hnp-98701b 및 hnp-98701c의항암제로서의 용도와 이의 제조방법 및 이를 유효성분으로함유하는 항암제용 약학적 조성물
ATE529110T1 (de) * 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
JP2006528692A (ja) * 2003-05-08 2006-12-21 ジ ユニバースティ オブ ミシシッピー 低酸素症への細胞応答を阻害するサウルルスセルヌウス化合物
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
CN102282142A (zh) * 2008-11-14 2011-12-14 拜耳先灵制药股份公司 取代的芳族化合物和它们的用途
US8946289B2 (en) * 2008-11-19 2015-02-03 Duke University Manassatin compounds and methods of making and using the same
CN102795975B (zh) * 2011-05-27 2016-03-09 中国医学科学院药物研究所 三白脂素结构简化物,其制法和其药物组合物与用途
FR2998307A1 (fr) * 2012-11-19 2014-05-23 Centre Nat Rech Scient Modele chimique d'une maladie neurodegenerative, procede de preparation et utilisations
EP3371791A1 (en) * 2015-11-04 2018-09-12 Telefonaktiebolaget LM Ericsson (publ) Method of providing traffic related information and device, computer program and computer program product

Also Published As

Publication number Publication date
RU2017115036A (ru) 2018-11-30
ES2703579T3 (es) 2019-03-11
TWI719952B (zh) 2021-03-01
BR112017008057A2 (pt) 2017-12-26
LT3212622T (lt) 2019-01-10
US9878990B2 (en) 2018-01-30
SI3212622T1 (sl) 2019-02-28
AU2015340584B2 (en) 2019-11-07
RU2704017C2 (ru) 2019-10-23
CN107074777B (zh) 2020-10-02
HUE041581T2 (hu) 2019-05-28
DK3212622T3 (en) 2019-01-21
PL3212622T3 (pl) 2019-03-29
BR112017008057B1 (pt) 2023-02-07
JP6644067B2 (ja) 2020-02-12
PT3212622T (pt) 2018-12-18
CY1121388T1 (el) 2020-05-29
RU2017115036A3 (es) 2019-04-26
AR102481A1 (es) 2017-03-01
IL251930A0 (en) 2017-06-29
CA2963601A1 (en) 2016-05-06
KR102598818B1 (ko) 2023-11-03
SG11201702555UA (en) 2017-04-27
JP2017532362A (ja) 2017-11-02
AU2015340584A1 (en) 2017-04-27
CA2963601C (en) 2023-01-31
WO2016066742A1 (en) 2016-05-06
MX375725B (es) 2025-03-06
EP3212622B1 (en) 2018-09-26
CN107074777A (zh) 2017-08-18
TW201625553A (zh) 2016-07-16
HRP20182167T1 (hr) 2019-02-08
US20170313674A1 (en) 2017-11-02
IL251930B (en) 2018-12-31
EP3212622A1 (en) 2017-09-06
KR20170072226A (ko) 2017-06-26
EP3015459A1 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2018006148A (es) Inhibidores de cxcr2.
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
MA39749A (fr) Dérivés de pipéridine-dione
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
MX382261B (es) Derivados heterociclicos y uso de los mismos.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
PH12018500903A1 (en) Pyranodipyridine compound
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
ECSP16096831A (es) Derivados de naftiridinadiona
JOP20200030A1 (ar) مركب خماسي الحلقة
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.

Legal Events

Date Code Title Description
FG Grant or registration